2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses targeting HER2 in early-stage breast cancer.
Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses targeting HER2 in early-stage breast cancer.
Verma says that data have shown that trastuzumab for 1 year leads to a reduction in breast cancer recurrence by about 40% and that survival improves, in relative terms, by about 40%. Further, 9 weeks of trastuzumab also appears to be beneficial, though data were not statistically significant. In comparison to 6 months, 1 year of trastuzumab proved to be a better option in a trial, though the primary endpoint of non-inferiority was not met. The question of duration of treatment with trastuzumab still needs to be definitively answered, but 1 year is the standard of care now.
With respect to a non-anthracycline-based approach, the combination of weekly paclitaxel and trastuzumab has shown to be well tolerated and effective. Verma says this combination represents a great option for patients who have tumors up to 2 cm.
Related Content: